Display options
Cite
Getie A, Alemnew B. Tuberculosis Treatment Outcomes and Associated Factors Among Patients Treated at Woldia General Hospital in Northeast Ethiopia: An Institution-Based Cross-Sectional Study. Infect Drug Resist. 2020;13:3423-3429doi: 10.2147/IDR.S275568.
Getie, A., & Alemnew, B. (2020). Tuberculosis Treatment Outcomes and Associated Factors Among Patients Treated at Woldia General Hospital in Northeast Ethiopia: An Institution-Based Cross-Sectional Study. Infection and drug resistance, 133423-3429. https://doi.org/10.2147/IDR.S275568
Getie, Addisu, and Alemnew, Birhan. "Tuberculosis Treatment Outcomes and Associated Factors Among Patients Treated at Woldia General Hospital in Northeast Ethiopia: An Institution-Based Cross-Sectional Study." Infection and drug resistance vol. 13 (2020): 3423-3429. doi: https://doi.org/10.2147/IDR.S275568
Getie A, Alemnew B. Tuberculosis Treatment Outcomes and Associated Factors Among Patients Treated at Woldia General Hospital in Northeast Ethiopia: An Institution-Based Cross-Sectional Study. Infect Drug Resist. 2020 Oct 06;13:3423-3429. doi: 10.2147/IDR.S275568. eCollection 2020. PMID: 33116661; PMCID: PMC7547773.
Copy Download .nbib Format: NLM
Share it on

Infect Drug Resist. 2020 Oct 06;13:3423-3429. doi: 10.2147/IDR.S275568. eCollection 2020.

Tuberculosis Treatment Outcomes and Associated Factors Among Patients Treated at Woldia General Hospital in Northeast Ethiopia: An Institution-Based Cross-Sectional Study.

Infection and drug resistance

Addisu Getie, Birhan Alemnew

Affiliations

  1. Department of Nursing, College of Health Sciences, Woldia University, Woldia, Ethiopia.
  2. Department of Medical Laboratory, College of Health Sciences, Woldia University, Woldia, Ethiopia.

PMID: 33116661 PMCID: PMC7547773 DOI: 10.2147/IDR.S275568

Abstract

BACKGROUND: Tuberculosis remains a major global health problem. It causes ill-health among millions of people each year and ranks alongside the human immunodeficiency virus (HIV) as a leading cause of death worldwide. For effective tuberculosis control, it is a prerequisite to detect the cases as early as possible and to ensure that the tuberculosis patients complete their treatment and get cured. However, the burden of the problem is still a national issue, and there is a scarcity of research to show treatment outcomes and associated factors of tuberculosis at the North Wollo Zone, specifically Woldia.

METHODS: Institution-based, retrospective register-based data were collected from medical records of tuberculosis patients from 2015 up to 2018 at Woldia General Hospital. The data were analyzed using SPSS version 24, and multiple logistic regression methods were used to investigate the association between independent and dependent variables. A P-value of less than 5% was considered statistically significant in the final model.

RESULTS: The prevalence of successful tuberculosis treatment outcomes was 80.7%. Among all patients, 73% were pulmonary tuberculosis cases. This study results show that age less than 24 years old [AOR: 4.7; 95% CI (1.3-10.1)], male sex [AOR: 2.8; 95% CI (2.1-4.8)], year of registration in 2018 [AOR: 4.8; 95% CI (3.9-7.4)], and HIV negative status [AOR: 3.9; 95% CI (1.4-10.7)]  were found to be significantly associated factors with the treatment outcomes of tuberculosis.

CONCLUSION: The study showed that nearly 20% of tuberculosis patients had an unsuccessful treatment outcome. Older age, female sex, year of registration in 2015, and being HIV positive were found significantly associated with poor tuberculosis treatment outcomes. Therefore, targeted measures should be considered to decrease poor TB treatment outcomes among high-risk patients through careful monitoring, making the DOTs program more accessible, counseling, and linking HIV patients.

© 2020 Getie and Alemnew.

Keywords: TB treatment; successful treatment outcome; treatment outcome

Conflict of interest statement

The authors declare that they have no competing interests for this work.

References

  1. BMC Res Notes. 2019 Apr 5;12(1):209 - PubMed
  2. Afr Health Sci. 2014 Mar;14(1):157-66 - PubMed
  3. PLoS One. 2016 Feb 26;11(2):e0150560 - PubMed
  4. Braz J Infect Dis. 2016 Nov - Dec;20(6):635-636 - PubMed
  5. J Antimicrob Chemother. 2014 Feb;69(2):331-42 - PubMed
  6. BMC Public Health. 2009 Oct 04;9:371 - PubMed
  7. Tuberc Res Treat. 2019 Apr 1;2019:1503219 - PubMed
  8. PLoS One. 2018 Oct 18;13(10):e0205468 - PubMed
  9. Eur J Immunol. 2013 Aug;43(8):2114-25 - PubMed
  10. Afr Health Sci. 2016 Sep;16(3):663-670 - PubMed
  11. BMC Res Notes. 2018 Jan 15;11(1):25 - PubMed
  12. Public Health Action. 2017 Mar 21;7(1):32-38 - PubMed
  13. J Infect Dev Ctries. 2015 Aug 29;9(8):821-8 - PubMed
  14. Tuberc Res Treat. 2016;2016:1294876 - PubMed
  15. PLoS One. 2019 Oct 30;14(10):e0224025 - PubMed
  16. BMC Public Health. 2012 Jul 23;12:537 - PubMed
  17. Ethiop J Health Sci. 2018 May;28(3):347-354 - PubMed
  18. Antimicrob Agents Chemother. 2017 Apr 24;61(5): - PubMed
  19. BMC Pulm Med. 2018 Feb 20;18(1):37 - PubMed
  20. Int J Tuberc Lung Dis. 2018 Jan 1;22(1):17-25 - PubMed
  21. BMC Bioinformatics. 2016 Jan 11;17 Suppl 1:3 - PubMed
  22. PLoS One. 2020 Apr 29;15(4):e0232468 - PubMed
  23. Immunol Rev. 2011 Mar;240(1):235-51 - PubMed

Publication Types